Skip to main content
. Author manuscript; available in PMC: 2010 Aug 15.
Published in final edited form as: J Immunol. 2009 Jul 22;183(4):2365–2372. doi: 10.4049/jimmunol.0900721

Figure 5. ChNKG2D T cell treatment increases T cell trafficking to the tumor site.

Figure 5

(A) ID8-GFP-tOva cells or (B) ID8-GFP cells were injected i.p. One week later, mice were treated i.p. with wtNKG2D T cells (white bars), chNKG2D T cells (black bars), or PBS (grey bars), and CFSE-labeled OT-I T cells were transferred i.v. Absolute number of OT-I T cells in the mediastinal lymph node and peritoneal cavity was determined three days after T cell injection. The average of each group (n=4) is shown + SD. Treatment with chNKG2D T cells significantly increased OT-I T cell trafficking in vivo compared to control treated mice (*-p<0.05). Data are representative of 2 independent experiments.